88 -9 (95) 2026 - Ikramova F.A., Nurboev F.E., Axmedov N.I. - ARTERIAL STIFFNESS, ECG REPOLARIZATION ABNORMALITIES AND ARRHYTHMIC RISK IN TYPE 2 DIABETIC CARDIOMYOPATHY: EFFECT OF SGLT2 INHIBITOR-FINERENONE-BASED COMBINATION THERAPY

ARTERIAL STIFFNESS, ECG REPOLARIZATION ABNORMALITIES AND ARRHYTHMIC RISK IN TYPE 2 DIABETIC CARDIOMYOPATHY: EFFECT OF SGLT2 INHIBITOR-FINERENONE-BASED COMBINATION THERAPY

Ikramova F.A., Nurboev F.E., Axmedov N.I. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This study evaluated the dynamics of arterial stiffness, carotid atherosclerosis, ECG repolarization parameters and Holter-derived heart rate variability in 87 patients with type 2 diabetes and cardiomyopathy over a 6-month treatment period. The main group (n=41) received complex therapy (SGLT2 inhibitor, finerenone, metabolic support), the comparison group (n=46) received standard therapy. Pulse wave velocity decreased from 12.4±0.4 to 9.6±0.3 m/s in the main group versus 11.2±0.4 m/s in the comparison group (p=0.001). Corrected QTc (Bazett) shortened from 462.4±6.2 to 431.6±5.1 ms in the main group, returning to the normal range, while remaining borderline-pathological in the comparison group (452.8±5.9 ms; p=0.007). QT dispersion decreased by 28.0% in the main group versus 7.5% in the comparison group. These findings indicate that complex metabolic therapy provides a significant reduction in arterial stiffness and ventricular repolarization abnormalities, plausibly mediated through normalization of magnesium and potassium balance, supporting its antiarrhythmic potential in diabetic cardiomyopathy.

Keywords: diabetic cardiomyopathy, arterial stiffness, pulse wave velocity, QTc interval, QT dispersion, heart rate variability, SGLT2 inhibitors, finerenone.

First page

600

Last page

603

For citation:Ikramova F.A., Nurboev F.E., Axmedov N.I. - ARTERIAL STIFFNESS, ECG REPOLARIZATION ABNORMALITIES AND ARRHYTHMIC RISK IN TYPE 2 DIABETIC CARDIOMYOPATHY: EFFECT OF SGLT2 INHIBITOR-FINERENONE-BASED COMBINATION THERAPY//New Day in Medicine 9(95)2026 600-603 https://newdayworldmedicine.com/en/new_day_medicine/9-95-2026

LIST OF REFERENCES

1. Elevated estimated pulse wave velocity and the risk of type 2 diabetes in non-obese young adults: a longitudinal cohort study. 2025. PMC12143030.
2. Independent association of estimated pulse-wave velocity with all-cause mortality in individuals with type 2 diabetes. QJM. 2024;117(7):495-503.
3. Prognostic value of pulse wave velocity for cardiovascular disease risk stratification in diabetic patients: a systematic review and meta-analysis. ScienceDirect. 2024.
4. Exploring the link between atherosclerosis indicators and QT interval in type 2 diabetes: a retrospective cross-sectional analysis. 2025. PMC13195229.
5. Association of atherogenic serum lipids and platelet activation with changes in arterial stiffness in patients with type 2 diabetes. 2025. PMC11933956.
6. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845.
7. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antsiferov M, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192.
8. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639-653. doi:10.1002/dmrr.1239.

   file

   download